Servier receives approval from European Commission for Voranigo® (vorasidenib), first targeted therapy for Patients with Grade 2 IDH-mutant Glioma.

Suresnes, France, September 22nd 2025 – Servier, an independent international pharmaceutical group governed by a foundation, today announces that the EC has approved Voranigo® (vorasidenib) for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and who are not in immediate need of radiotherapy or chemotherapy. The decision to approve Voranigo®...